Quantisnow Logo
Dashboard

CooperCompanies Recognized as a Best Workplace for Innovators

$COO
Ophthalmic Goods
Health Care
Get the next $COO alert in real time by email

SAN RAMON, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) --  CooperCompanies (NASDAQ:COO) announced today that the company has been recognized as a Best Workplace for Innovators by Fast Company—a leading business media brand with an editorial focus on innovation—for creating a culture of employee development and belonging that inspires innovation and the development of new products and advocacy initiatives that aim to improve standard-of-care. This prestigious award recognizes organizations from around the world and across a variety of industries that demonstrate a commitment to encouraging and developing innovation at all levels.

"Our work matters to us; you can see it in our culture and everything we do," said Al White, President and CEO of CooperCompanies. "We're making significant investments in ourselves and in our people, driving innovation across Cooper that is ultimately improving patient outcomes. I'm incredibly proud of this accolade—our work improving lives around the world is something to celebrate!"

In addition to being recognized as a Best Workplace for Innovators, CooperCompanies was also included on the 2024 Top 100 Inspiring Workplaces in North America list and achieved a perfect score of 100 on the Human Rights Campaign's Corporate Equality Index earlier this year.

About CooperCompanies

CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Contacts:

Media:

Jess Bernstein

Director, Corporate Communications

communcations@cooperco.com 		Investors:

Kim Duncan

Vice President, Investor Relations & Risk Management

ir@cooperco.com 





Primary Logo

Get the next $COO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COO

DatePrice TargetRatingAnalyst
8/29/2024$115.00 → $120.00Overweight
Piper Sandler
7/16/2024$107.00 → $115.00Hold → Buy
Jefferies
3/19/2024$125.00Neutral → Buy
Redburn Atlantic
3/13/2024$100.00 → $120.00Neutral → Overweight
JP Morgan
2/6/2024Sector Weight
KeyBanc Capital Markets
10/30/2023$380.00Buy
BofA Securities
10/5/2023$390.00 → $343.00Overweight → Neutral
Redburn Atlantic
5/30/2023$410.00Equal-Weight
Morgan Stanley
More analyst ratings

$COO
 Press Releases

Fastest customizable press release news feed in the world

See more

  • CooperCompanies Announces First Quarter 2025 Results

    SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

    $COO
    Ophthalmic Goods
    Health Care

  • CooperCompanies Announces Release Date for First Quarter 2025

    SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

    $COO
    Ophthalmic Goods
    Health Care

  • CooperCompanies to Present at the J.P. Morgan Healthcare Conference

    SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and Coop

    $COO
    Ophthalmic Goods
    Health Care

$COO
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$COO
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$COO
 SEC Filings

See more

$COO
 Leadership Updates

Live Leadership Updates

See more

  • Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

    SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

    $COO
    Ophthalmic Goods
    Health Care

  • CooperCompanies Appoints Cynthia Lucchese to Board of Directors

    SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board. "We are pleased to welcome Cindy to Cooper's Board of Directors," said Al White, President and CEO of CooperCompanies. "She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders." Lucchese currentl

    $COO
    Ophthalmic Goods
    Health Care

$COO
 Financials

Live finance-specific insights

See more

  • CooperCompanies Announces First Quarter 2025 Results

    SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

    $COO
    Ophthalmic Goods
    Health Care

  • CooperCompanies Announces Release Date for First Quarter 2025

    SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

    $COO
    Ophthalmic Goods
    Health Care

  • CooperCompanies Announces Fourth Quarter and Full Year 2024 Results

    SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically.Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%.Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting o

    $COO
    Ophthalmic Goods
    Health Care

$COO
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more